Cend Therapeutics

Cend Therapeutics is a clinical-stage biotech company focused on a novel approach to provide more effective treatments for solid tumor cancer patients.

Pancreatic

Breast

Gastric

OUR

PIPELINE

Liver

Lung

Brain

Learn More

Latest News

June 29, 2021

Cend Therapeutics’ CEND-1 Granted Fast Track Designation for Pancreatic Cancer

View More

OUR

SCIENCE

View More

PARTNERS AND
INVESTORS

Cend and our investors are committed to delivering better therapies for a range of solid tumor cancer patients. We work with partners who are leaders in their fields to help them better address cancers for the patients they serve.

View More